IPP Bureau
Elpiscience and Astellas collaborate for novel bispecific macrophage engager
By IPP Bureau - December 28, 2023
Elpiscience will receive up to US $37 million, including the upfront payment and license option fees
Mandaviya virtually launches 'MedTech Mitra'
By IPP Bureau - December 27, 2023
MedTech Mitra is a platform that will help the young talents of the country by holding their hands and giving them final shape to their research, knowledge and logic
Sonowal and Khandu lay foundation stone for capacity expansion at NEIAFMR
By IPP Bureau - December 27, 2023
NEIAFMR to be developed as the national hub for folk medicine
Apollo Hospitals Enterprise reduces stake in Apollo Home Healthcare
By IPP Bureau - December 27, 2023
AHHL is primarily engaged in nursing care, in home primary care, physiotherapy at home, sample collection, post-operative/post-surgical care
Lupin receives USFDA approval for Loteprednol Etabonate Ophthalmic Suspension, 0.2%
By IPP Bureau - December 27, 2023
Loteprednol Etabonate Ophthalmic Suspension, 0.2%, is indicated for the temporary relief of the signs and symptoms of seasonal allergic conjunctivitis
Eugia Pharma Specialities receives USFDA final approval for Posaconazole Injection
By IPP Bureau - December 27, 2023
The product is expected to be launched in December 2023
Pigeon Singapore, LyondellBasell collaborate to incorporate bio-circular plastic in nursing bottles
By IPP Bureau - December 26, 2023
The LyondellBasell CirculenRenew polymers are made from renewable feedstocks derived from bio-based wastes
GenSci launches global innovation hub in Shanghai
By IPP Bureau - December 26, 2023
The establishment of the facility demonstrates the company's commitment to delivering differentiated solutions to gynecology and pediatrics challenges
AstraZeneca to acquire China's Gracell Biotechnologies for US $1.2 billion
By IPP Bureau - December 26, 2023
Furthering cell therapy ambition across oncology and autoimmune diseases
Roche receives USFDA’s priority review to Xolair for food allergies based on positive NIH Phase III study results
By IPP Bureau - December 26, 2023
If approved, Xolair would be the first medicine to reduce allergic reactions to multiple foods following an accidental exposure
Wainua granted first-ever regulatory approval in the US for improving neuropathy impairment
By IPP Bureau - December 26, 2023
US FDA approval based on NEURO-TTRansform Phase III results
BioVaxys executes LoI for major Immunotherapeutics technology acquisition
By IPP Bureau - December 26, 2023
BioVaxys has been granted exclusivity while the parties work in good faith on the drafting of a definitive agreement
Astellas completes acquisition of Propella Therapeutics
By IPP Bureau - December 26, 2023
Astellas has acquired abiraterone decanoate being developed by Propella to treat prostate cancer
Eugia's East Windsor facility gets 10 observations from USFDA
By IPP Bureau - December 25, 2023
The plant is yet to start commercial operations
Stelis Biopharma updates on receipt of consideration from Syngene
By IPP Bureau - December 25, 2023
Syngene has completed a payment of Rs. 158.2 crores on December 22, 2023 in addition to the initial payment of Rs. 395 crores made on December 1, 2023
